Collaborative Tech to Develop New, Affordable Drugs
JAYKUMAR MENON — CO-FOUNDER, OPEN PHARMA
AMONG THE MANY SOCIETAL shortcomings the pandemic has laid bare, the failure to get drugs and vaccines to many people who need them is one of the most painful and urgent. For many people around the world, the shots that arrived so expeditiously to those in the rich countries are still out of reach. “It’s an outrage that billions of people have no access to the new vaccines,” says human rights lawyer Jaykumar Menon. “We need a new model.”
After years working as a lawyer and advocate, Menon saw a way to potentially help millions of people realize the “human right to healthcare.” Inspired by the software world’s concept of “Open Source,” where developers make their code freely available for others to use, adapt and share, in 2014, he co-founded the Open Source Pharma Foundation (OSPF) with a team of public health and pharmaceutical industry experts. Their goal: to revolutionize the way pharmaceuticals are developed by shifting research from expensive, proprietary, profit-driven strategies to an emphasis on sharing resources and research insights.
One troublesome consequence of the reliance on big pharmaceutical companies to bring a drug from lab to market is that it provides no incentive to invest in diseases that take a high toll on low-income nations and a dearth of treatments for rare conditions, where the pay-off for developing a new drug is seen as too small to make sense.
Esta historia es de la edición December 24, 2021 de Newsweek Europe.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición December 24, 2021 de Newsweek Europe.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor? Conectar
ARABIAIAN MIGHT
SAUDI ARABIA'S INCREASING STRENGTH MEANS IT NOW HAS MUCH MORE CLOUT WITH ITS PARTNERS, INCLUDING THE U.S.
Bringing Trump's Trial to Life
Sketch artist Isabelle Brourman tells Newsweek what it was like covering the former president’s court case
Iran Examines the Nuclear Option
Tehran’s rhetoric could spark an arms race in the Middle East like never before
Climate Conviction at What Price?
Fifty years ago experts doubted Americans would pay to save the environment. Only some of their fears are still true
Most Loved Workplaces 2024
THE WORLD'S MOST LOVED WORKPLACES ARE REMARKABLE FOR A variety of reasons.
Maya Hawke
MAYA HAWKE WEARS MANY HATS: ACTOR, WRITER,SINGER. BUT FOR Hawke, everything comes down to words.
Jacob Anderson
ANNE RICE'S NOVEL INTERVIEW WITH THE Vampire has a rabid fan base, intensely protective of the story and any adaptations of it.
VOTES OF NO CONFIDENCE
Why recent U.K. election results will ring alarm bells for Joe Biden
BIDEN'S BATTLEGROUND ELECTION
A small number of Democrats PROTESTING the president's support for Israel's war in Gaza could PREVENT him from winning a second term
'It's Time to Treat Addiction Like Cancer'
Both are serious illnesses but, unlike those struggling with substance use disorders, didn’t face shame and stigma when seeking help over my tumors